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Padionuclide Imaging for the
etection of Inflammation in Vulnerable Plaques
ohn R. Davies, BSC, MBBS, MRCP,* James H. F. Rudd, PHD, MRCP,†
eter L. Weissberg, MD, FRCP,* Jagat Narula, MD, PHD, FACC‡
ambridge, United Kingdom; New York, New York; and Irvine, California
Imaging of atheromatous plaques has traditionally centered on assessing the degree of luminal
stenosis. More recently it has become clear that the vulnerable atherosclerotic plaques
responsible for the majority of life-threatening syndromes are characterized by high numbers
of inflammatory cells and proteins. This has highlighted the urgent need for suitable imaging
techniques that can identify and quantify levels of inflammation within atheromatous lesions.
Positron emission tomography and single-photon emission computed tomography imaging
hold promise in this regard. Tracer compounds capable of assessing macrophage recruitment,
foam cell generation, matrix metalloproteinase production, macrophage apoptosis, and
macrophage metabolism have been developed and tested in the carotid and peripheral
circulation. The identification of inflamed lesions within the coronary circulation, however,
remains elusive owing to small plaque size, cardiac and respiratory motion, and lack of a
suitable specific nuclear tracer. (J Am Coll Cardiol 2006;47:C57–68) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.049American College of Cardiology Foundation
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cost of the techniques for imaging atherosclerotic lesions
ave been aimed at providing anatomic detail of plaque
ize and luminal narrowing. Few techniques are able to
rovide quantifiable information regarding the cellular,
iochemical, and molecular composition of lesions that
ictate stability of the plaque. Thus, our ability to
dentify plaques at risk of rupture and therefore patients
t risk of complications such as myocardial infarction and
hromboembolic stroke remains limited; however, by label-
ng tracer compounds that are capable of identifying impor-
ant cellular or molecular processes with radioactive isotopes
also known as radionuclides), there is the potential to
rovide clinicians with a powerful imaging tool with which
o identify vulnerable plaques, and patients at high risk of
therosclerotic complications. In addition, because of its
on-invasive nature, radionuclide imaging could be used
o monitor the effects of therapeutic interventions, both
stablished and experimental.
Over the last twenty years it has become clear that
nflammatory cells and proteins play a critical role in
estabilization of atherosclerotic plaques (1) and thus pro-
ide an obvious target for nuclear imaging of the vulnerable
esion. This article aims to review the progress made within
his field.
HE PRINCIPLES OF NUCLEAR IMAGING IN
ELATION TO IMAGING OF ATHEROSCLEROSIS
maging with radionuclide tracer compounds is a multistage
rocess. It begins with production of the radionuclide and
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ork; and the ‡University of California-Irvine School of Medicine, Irvine, California.
ork of Drs. Davies and Weissberg is supported by grants from the British Heart
oundation. Dr. William A. Zoghbi acted as guest editor.i
Manuscript received June 16, 2005; revised manuscript received October 10, 2005,
ccepted November 16, 2005.ts conjugation with a tracer compound. This is followed by
dministration of the tracer compound to the patient and its
ubsequent detection by techniques such as single-photon
mission computed tomography (SPECT) and positron
mission tomography (PET). The raw data collected by the
canner then have to be corrected to account for errors due
o attenuation, scatter, random decay events, and dead time,
nd finally computer reconstruction allows for the produc-
ion of two-dimensional and three-dimensional topograph-
cal images revealing the distribution of the tracer com-
ound within the tissues in the field of view.
The small size of most atherosclerotic lesions and their
natomical proximity to other structures places exacting
emands on nuclear imaging systems. This is certainly the
ase with coronary lesions, which have a cross-sectional area
f typically 10 mm2, are subject to cardiac motion, and lie
djacent to the myocardium, a substrate for “background”
racer uptake. Ideally, tracers for atheroma imaging should
ind specifically to plaque constituents and should be
apidly cleared from the circulation to allow for sufficient
ontrast between the plaque and the blood pool. Uptake in
djacent tissues should also be minimal. Most nuclear
maging studies carried out so far have tended to concen-
rate on the larger lesions present in carotid, aortic, and
liofemoral arteries. In this article discussion will be limited
o those methods that target important inflammatory com-
onents of the vulnerable plaque and that have either proved
uccessful or that show promise for the future.
HE BIOLOGY OF PLAQUE INFLAMMATION
dvanced atherosclerotic lesions comprise a lipid-rich core
overed by a smooth muscle cell and matrix-rich fibrous cap.
he vulnerable plaque, whether it be present in coronary,
arotid, or peripheral arteries is typified by an abundance of
nflammatory cells and proteins (2–4), all of which provide
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Nuclear Imaging of Vulnerable Plaque April 18, 2006:C57–68otential targets for radionuclide tracers. Macrophages play
central role in the destabilization of atherosclerotic lesions.
irculating monocytes are recruited to atheromatous lesions
n response to the expression of adhesion molecules and
hemotactic proteins such as monocyte chemotactic protein
MCP)-1 (5). Once recruited, they differentiate into mac-
ophages and ingest oxidized lipoproteins, thereby generat-
ng foam cells (6). Foam cells and newly recruited macro-
hages secrete a host of pro-inflammatory cytokines as well
s enzymes such as matrix metalloproteinases (MMP) that
reakdown the connective tissue of the fibrous cap resulting
n structural changes that reduce its ability to resist the
echanical forces placed upon it by the flowing blood (7).
oam cells in the atherosclerotic lesions frequently exhibit
ndoplasmic reticular stress, which is associated with phos-
hatidyl serine (PS) expression on the cell surface, which in
urn contributes to foam cell apoptosis (8). Extensive
pregulation of caspases is seen in atherosclerotic lesions
9), and overt apoptosis of macrophages is commonly
bserved in fibrous caps at the site of plaque rupture;
poptosis further augments surface PS expression (10).
Radionuclide tracers have been developed that can iden-
ify some of the important pathways associated with plaque
nstability, such as macrophage recruitment, foam cell for-
ation, matrix breakdown enzymes, macrophage metabo-
ism, and apoptosis (Fig. 1). Table 1 provides a summary of
ome of the studies that have been carried out.
MAGING OF MONOCYTE RECRUITMENT
onocyte chemotactic protein-1 labeled with iodine-125
125I) has been shown to accumulate selectively in lipid-rich,
acrophage-rich regions of experimental atherosclerosis in
abbits where the radiotracer uptake closely correlated with
he severity of lesions (11). The ratio of radioactivity in
laque to normal vessel was 6:1. Furthermore, there was a
trong correlation between percent injected dose per gram
ccumulation of 125I-MCP-1 in the atherosclerotic lesions
Abbreviations and Acronyms
CT  computed tomography
FDG  fluorine-18–labeled deoxyglucose
HO-CGS 27023A  123I-labeled molecule
MCP-1  monocyte chemotactic protein-1
MDA2  malondialdehyde-2
MMP  matrix metalloproteinase
MRI  magnetic resonance imaging
oxLDL  oxidized low-density lipoprotein
PET  positron emission tomography
PS  phosphatidyl serine
SPECT  single-photon emission computed
tomography
Tc  technetium
TIA  transient ischemic attack
WHHL  Wantanabe heritable
hyperlipidemicnd quantitative estimates of the number of macrophages mer unit area (r 0.85, p 0.0001). Encouragingly, plasma
learance of the tracer was also rapid with a clearance
alf-life of 10 min, suggesting that external imaging of
nflamed plaques with MCP-1 tracers might be possible.
At present no in vivo imaging studies using the afore-
entioned tracer compounds have been published. There-
ore, it remains uncertain as to whether this approach to
on-invasive external imaging of macrophage recruitment is
chievable in vivo in man; however, the importance of
acrophage recruitment with regard to plaque instability
ustifies the ongoing efforts of investigators in this field.
MAGING OF LIPOPROTEIN
HAGOCYTOSIS AND FOAM CELL GENERATION
ulnerable lesions are characterized by high levels of low-
ensity lipoprotein accumulation, oxidation, and phagocy-
osis by plaque macrophages and foam cells. Lipid metab-
lism therefore provides a suitable target for identifying
igh-risk plaques.
Oxidized low-density lipoprotein (oxLDL) particles have
een successfully radio-labeled, allowing investigators to
dentify lipid accumulation within macrophages and foam
ells present in atheromatous plaques. Iuliano et al. (12)
sed 99mtechnetium (Tc)-oxLDL to successfully image
ymptomatic human carotid lesions in vivo. They found that
ptake of 99mTc-oxLDL by carotid plaques was significantly
igher compared with normal carotids (p  0.02). Uptake
f 99mTc-oxLDL above that of the normal carotid artery
as observed in 10 of 11 carotid plaques (91%, confidence
imits 58.7 to 99.8). No correlation between the degree of
tenosis and the target to background uptake ratio was seen.
Given that the clinical utility of radiolabeled autologous
xLDL is likely to be limited owing to the time-consuming
reparation process, several groups have synthesized and
ested antibody tracers that bind to epitopes on the oxLDL
olecule. The majority of studies performed thus far have
sed radiolabeled malondialdehyde-2 (MDA2), a prototype
urine monoclonal antibody that binds to the malondial-
ehyde epitope on the oxLDL molecule. Experiments in
ypercholesterolemic apolipoprotein E null mice and Wan-
anabe heritable hyperlipidemic (WHHL) rabbits have shown
hat lipid-rich lesions accumulated approximately 20 times
ore 125I-MDA2 than normal arterial tissue (13). Immuno-
istochemistry confirmed co-localization of 125I-MDA2 up-
ake with macrophage foam cells. In an ex vivo autoradiogra-
hy study, 125I-MDA2 has been shown to have the capability
o track changes in macrophage foam cell density after dietary
anipulation (14). Immunohistology revealed that decreased
ptake of 125I-MDA2 after dietary plaque regression did not
orrelate with a decrease in plaque size but was associated with
decrease in macrophage foam cell number, an increase in
ascular smooth muscle cells, and a higher collagen content
15). These results suggest that MDA-2 could be used as a
arker of plaque stability. Preliminary studies carried out on
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13) have confirmed the feasibility of in vivo gamma imaging
f aortic plaque (Fig. 2); however, a visible signal was only seen
n four of seven WHHL rabbits, and no quantification of the
n vivo images was attempted. Therefore, the in vivo imaging
apability of this technique remains in doubt.
In an attempt to increase the amount of tracer entering
he plaque, genetically engineered antibodies against human
xLDL have been synthesized. Their small molecular size
hould enable higher lesion-to-blood ratios, which should
llow for more effective in vivo imaging. In vitro and ex
ivo experiments carried out in experimental animal
odels and on excised human atheroma have given prom-
sing results (16), but we will have to await the outcome of
n vivo imaging studies before the clinical potential of this
racer can be predicted. Despite the lack of in vivo human
ata, this approach holds the most promise in terms of
maging and quantifying lipid transport in advanced human
igure 1. Targets for nuclear imaging of plaque inflammation. Schemat
otential targets for the identification of vulnerable plaques. CCR-2  che
ransporter; IEL internal elastic lamina; MCP-1monocyte chemotact
ipoprotein; PS  phosphatidyl serine; SR-A  scavenger receptor-A.esions. tMAGING OF PLAQUE MMP
laque instability occurs as a result of excessive secretion of
MP enzymes that break down the connective tissue matrix
f the plaque. When activated by oxLDL and pro-
nflammatory cytokines, macrophages secrete inactive MMP,
ncluding interstitial collagenases (MMP-1), gelatinase B
MMP-9), and stromolysins (MMP-3), which are activated
n situ by plasmin (17,18). Immunohistochemistry shows
hat MMP production is predominantly in the vicinity of
acrophages in human coronary atherosclerotic lesions
19). Kopka et al. (20) have successfully synthesized a
umber of synthetic radiolabeled MMP inhibitors that bind
o the active zinc(II) ion on a broad spectrum of MMPs.
hey studied a 123I-labeled molecule (HO-CGS 27023A)
n apolipoprotein E null mice that had undergone carotid
rtery ligation followed by high-cholesterol diet to induce
apid development of atherosclerosis (21). They showed
resentation of inflammatory cells, molecules, and processes that present
ne receptor 2; CD36; cluster differentiation 36; GLUT  glucose uptake
tein-1; MMPmatrix metalloproteinase; oxLDL oxidized low-densityic rep
mokihat, after injection of 123I-HO-CGS 27023A, uptake into
Table 1. Radionuclide Tracer Compounds Used to Image Inflammation in Atherosclerotic Lesions
Target Mechanism Target Cell/Molecule Tracer Animal/Human Successful In Vivo Imaging Notes
Macrophage
chemotaxis
CCR-2 125I-MCP-1 NZW rabbit aorta NA Excellent correlation with macrophage number.
Fast plasma clearance. Potential candidate
for coronary imaging but in vivo studies yet
to be reported.
LDL phagocytosis
and foam cell
generation
LDL 123I-LDL
99mTc-LDL
Human carotid
Human carotid, ileo-femoral
✓ SPECT
✓ SPECT
Long plasma half life of tracers necessitates
imaging several hours after tracer injection, a
problem that compromises clinical utility.
oxLDL 99mTc-oxLDL Human carotid ✓ SPECT Rapid plasma clearance c.f. native LDL tracers
make it a more promising candidate for
in vivo imaging; however, time-consuming
tracer production process.
99mTc-MDA2 Apo E / mouse
WHHL rabbit
✓ SPECT No human studies reported.
MMP activity MMP 123I-HO-CGS 27023A
111In-MMP inhibitor
Apo E / mouse carotid
NZW rabbit aorta
✓ SPECT
✓ SPECT
Encouraging pharmacokinetic and in vivo
imaging results. Has potential for coronary
imaging but no human studies reported
so far.
Apoptosis PS 99mTc-annexin-A5 NZW rabbit aorta,
human carotid
✓ SPECT Clinical applications in patients with carotid
disease. Potential for coronary imaging.
Macrophage
infiltration/activity
Autologous-monocytes 111In-monocyte Human X Time consuming tracer production. Unlikely to
be used for in vivo imaging.
Ama 131I-Ama-MoAb WHHL rabbit aorta X Slow plasma clearance—unsuccessful gamma
imaging.
GLUT 18FDG WHHL  NZW aorta
Human coronary, carotid,
aorta, and iliac
✓ PET Clinical potential in patients with carotid
disease. Myocardial uptake is likely to make
coronary imaging difficult to achieve in a
high proportion of patients.
Ama-MoAb  amino malonic acid monoclonal antibody; Apo E /  apolipoprotein E null; CCR  chemokine receptor; 18FDG  18-fluorodeoxyglucose; GLUT  glucose transporter protein; LDL  low-density lipoprotein;
MCP  monocyte chemotactic protein; MDA  molondialdehyde; MMP  matrix metalloproteinase; NA  not attempted; NZW  New Zealand White; oxLDL  oxidized low density lipoprotein; PET  positron emission
tomography; PS  phosphatidyl serine; SPECT  single photon emission computed tomography; WHHL  Wantanabe heritable hyperlipidaemic.
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April 18, 2006:C57–68 Nuclear Imaging of Vulnerable Plaqueesioned carotid arteries was significantly higher than nor-
al arterial tissue from the contralateral carotid artery and
arotid arteries from the sham and control mice (Fig. 3). In
ddition, pre-dosing mice with unlabeled ligand prevented
ptake, indicating a high level of specific binding. Clearance
f the tracer from the circulation was rapid, allowing for
lear plaque identification on gamma images. Ex vivo
amma counting of arteries from the lesioned mice con-
rmed uptake into the artery that was not found in the
ontralateral artery. Micro-autoradiography of the imaged
esions with 125I-HO-CGS 27023A confirmed co-localization
f tracer distribution and MMP-9 immunostaining.
A similar broad-spectrum MMP inhibitor radiolabeled
ith indium-111 has been used to image atherosclerotic
esions in New Zealand White rabbits induced by balloon
e-endothelialization of the abdominal aorta and dietary
anipulation (22). After intravenous injection of the tracer,
amma camera imaging revealed significantly higher aortic
racer uptake in those on a high-cholesterol diet than in
hose where the diet was interrupted with normal chow
igure 2. In vivo gamma camera images of experimental aortic atherom
reparations of Sudan-stained aortas from an apolipoprotein E null (ApoE
njected with 125I-MDA2, a murine antibody binding to malondialdehyde
nd B) represents plaque stained with Sudan IV, and black color (right pa
25I-MDA2 reflecting the presence of oxLDL. (C) shows the relationship
) represent in vivo imaging of atherosclerotic WHHL (D) and non-athe
s in Figure 1. Reprinted, with permission, from Tsimikas et al. (13).0.033 0.019% injected dose/g; lesion-to-non-lesion ratio f1:1). In turn, images confirmed that the animals on the
nterrupted diet regime had higher concentrations of tracer
ptake than the control animals that were maintained on a
holesterol-free diet (0.015  0.005% injected dose/g, p 
.01). Threshold analysis of histological sections showed a
ignificantly higher level of immunostaining for MMP in
he plaque segments that demonstrated high tracer uptake
elative to those with low uptake.
These preliminary observations suggest that MMP might
rove to be a suitable target for in vivo imaging of athero-
clerosis. Recent reports of 11C and 18F labeling of MMP
nhibitors also raise the possibility of PET imaging studies
23). The superior spatial resolution and tracer detection
ensitivity of PET would increase the chances of successful
oronary plaque imaging with radiolabeled MMP inhibitors.
MAGING MACROPHAGE STRESS
ND APOPTOSIS IN ATHEROSCLEROTIC PLAQUE
poptotic cells express PS on their cell surface, and there-
er injection of 99mtechnetium-malondialdehyde-2 (Tc-MDA2). En-face
mouse (A) and a Watanabe heritable hyperlipidemic (WHHL) rabbit (B)
density lipoprotein, a model oxLDL epitope. Red color (left panels in A
in A and B) in the corresponding autoradiograph represents accumulated
I-MDA2 uptake and plaque burden as measured by aortic weight. (D and
rotic New Zealand White (E) rabbits with 99mTc-MDA2. Abbreviationsa aft
/)
–low-
nels
of 125ore, nuclear imaging of PS expression might identify vulner-
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Nuclear Imaging of Vulnerable Plaque April 18, 2006:C57–68ble plaques at risk of rupture (24). This expectation might
e confounded by the likelihood of PS expression on other
onstituents of the plaque, such as platelets in overlying
hrombus, and on red blood cell membrane remnants in the
ecrotic core of the lesions; however, given that thrombus
nd intra-plaque hemorrhage are both associated with
laque vulnerability, this might not present a problem in
linical practice.
Annexin-A5 has a high affinity for the aberrantly ex-
igure 3. In vivo single-photon emission computed tomography imaging
esions with the tracer, 123I-HO-CGS 27023A. Representative planar
polipoprotein E-deficient (ApoE/) mice and (D) wild-type (WT) m
mol/l CGS27023A; (C) sham-operated; (D) WT; (E) quantitative up
xpressed as % injected dose. *p  0.05 between unblocked and pre-dosed
eflects metabolism of the original compound, because there is no inhibitio
t al. (21).ressed PS on the cell surface. Accordingly, 99mTc-labeled tnnexin-A5 has been used for non-invasive imaging of
xperimental atherosclerotic lesions in rabbits induced by
e-endothelialization of the infradiaphragmatic aorta fol-
owed by 12 weeks of a high-fat, high-cholesterol diet (24).
ll animals received radiolabeled annexin-A5 intravenously,
nd the abdominal aortic atherosclerotic lesions could be
bserved 2 to 3 h later. Ex vivo images clearly showed
ptake of radiotracer corresponding to the lesion distribu-
ion within the excised aorta and to tracer uptake seen on
uantification of matrix metalloproteinase activity in experimental carotid
s taken 10 min (left) and 120 min (right) after injection in (A to C)
weeks after carotid ligation. (A) Unblocked; (B) after pre-dosing with 6
f the radioligand in the carotid lesion; and (F) tissue uptake over time
al uptake. The signal in the abdominal cavity is non-specific and probably
r pre-dosing in all experiments. Reprinted, with permission, from Schafersand q
image
ice 4
take o
lesion
n aftehe in vivo images. There was no radiotracer uptake in areas
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April 18, 2006:C57–68 Nuclear Imaging of Vulnerable Plaqueithout grossly visible atherosclerotic lesions. As a control,
n annexin-A5 mutant that is incapable of binding to PS
id not accumulate in the lesions. Similarly, there was no
ocalization of 99mTc-annexin-A5 in control rabbits without
therosclerotic lesions. Annexin-A5 uptake in atheroscle-
otic lesions was approximately 10-fold greater than in the
on-atherosclerotic aortic wall. The mean percent-injected
ose per gram Annexin-A5 uptake in the specimens with
esions correlated with the histologic severity of atheroscle-
otic lesions; the radiotracer uptake demonstrated that
nnexin accumulation predominantly occurred in Ameri-
an Heart Association type IV lesions with only minimal
ptake in type II and III lesions. There was a direct
elationship of annexin-A5 uptake with macrophage burden
r  0.47, p  0.04) and the magnitude of histologically-
erified apoptosis. No association was observed between
mooth muscle cell burden and radiotracer uptake (r 0.08,
 0.73).
99mTc-annexin-A5 has subsequently been used to image
theroma in four patients with carotid vascular disease (25),
wo of whom had suffered a recent transient ischemic attack
TIA). Tc99m-annexin-A5 uptake was seen in the cervical
egion in the two patients with recent TIA. No uptake was
iscernable in the other two patients who had each suffered
TIA more than 6 months before imaging and who were
lso being treated with high dose statins (Fig. 4). All
atients underwent carotid endarterectomy after imaging.
he positive Tc99m-annexin-A5 uptake correlated with
laque macrophage content, whereas both patients with
egative annexin scans had smooth muscle cell-rich lesions.
igure 4. Single-photon emission computed tomography (SPECT) images
5. (A) shows transverse and coronal views obtained by SPECT in Patient
atient #1 had significant stenoses of both carotid arteries; however, th
istopathology of an endarterectomy specimen from Patient #1 (B, anti
eointima, with extensive binding of annexin-A5 (brown staining). In con
onths before imaging, do not show annexin-A5 uptake in the carotid
bstructive lesion on the affected side. Histopathological analysis of an endarterec
ells, with negligible binding of annexin-A5. ANT  anterior; L  left. Reprine of the two patients with recent TIA had a severe lesion
n the contralateral carotid but without annexin-A5 uptake.
lthough these studies suggest that annexin-A5 has prom-
se as an atheroma-imaging agent, it is too early to speculate
n its clinical utility. In addition, a lack of anatomical detail
n the emission scans makes it difficult to be sure that the
ptake is indeed related to atherosclerotic plaque. Since
ublication of the above studies, annexin-A5 has been
uccessfully conjugated with the positron emitting isotopes,
8F (26) and 124I (27), the latter having been successfully
maged in vivo in an experimental model of hepatocyte
poptosis. This could potentially afford more sophisticated
maging and quantification and allow the detection of
poptosis within coronary lesions.
MAGING OF PLAQUE MACROPHAGE ACTIVITY
ITH FLUORINE-18–LABELED DEOXYGLUCOSE PET
ositron emission tomography, in which paired 511 keV
amma rays are detected by a ring of specialized scintillation
etectors, has certain advantages over SPECT. Positron emis-
ion tomography can provide 4 to 5 mm resolution compared
ith 1 to 1.5 cm for SPECT. Positron emission tomogra-
hy images are derived from the detection of positron-
mitting radionuclides, such as carbon-11 and fluorine-18,
hich can be used to label various biochemical and metabolic
ubstrates. Positron emission tomography agents have the
otential to provide a better functional assessment of athero-
clerotic plaques than tracers used in conventional nuclear
stable atherosclerotic carotid artery lesions obtained with Tc99m-annexin-
ho had a left-sided transient ischemic attack (TIA) 3 days before imaging.
ke of Tc99m-annexin-A5 is evident only in the culprit lesion (arrows).
xin-A5 antibody) shows substantial infiltration of macrophages into the
SPECT images of Patient #2 (C), who had had a right-sided TIA three
on both sides. Doppler ultrasonography revealed a clinically significantof un
#1, w
e upta
–anne
trast,
regiontomy specimen from Patient #2 (D) shows a lesion rich in smooth-muscle
nted, with permission, from Kietselaer et al. (25).
i
P
m
t
a
b
h
u
c
F
t
v
s
p
f
u
m
c
r
c
s
s
c
t
c
e
p
F
T
5
f
a
p
h
a
a
I
u
o
a
R
h
a
n
v
e
w
a
w
a
p
e
u
F
(
s
c
F
C64 Davies et al. JACC Vol. 47, No. 8 Suppl C
Nuclear Imaging of Vulnerable Plaque April 18, 2006:C57–68maging, in part as a result of the higher spatial resolution of
ET.
Deoxyglucose competes with glucose for uptake into
etabolically active cells where it accumulates in proportion
o metabolic activity. When labeled with fluorine-18, its
ccumulation can be imaged and, importantly, quantified
y PET. Fluorine-18–labeled deoxyglucose (FDG) PET
as been used extensively to estimate myocardial glucose
tilization (28) and is becoming the imaging method of
hoice for identifying tumors (29). The recognition that
DG-PET might have a role in imaging inflammation led
o its use in diagnosing and following patients with systemic
asculitides (30,31). In one study of 20 patients with
uspected vasculitis, FDG-PET was reported to have 100%
ositive predictive value and 82% negative predictive value
or the diagnosis of vasculitis (31). It has been particularly
seful in diagnosing and monitoring the response to treat-
ent in Takayasu’s arteritis (32,33). Thus, FDG-PET
learly has the capacity to measure vascular inflammation.
The first studies to show that FDG-PET might have a
ole in imaging atherosclerosis were performed in
holesterol-fed rabbits. Vallabojosula et al. (34) showed that
ufficient FDG was taken up by macrophage-rich athero-
clerotic lesions in the aortic arch to be able to image in a
onventional human PET scanner. The same group showed
hat FDG uptake seemed to be related to macrophage
ontent of the plaque. With a similar model, Lederman
t al. (35) showed that a positron-sensitive fiber-optic probe
igure 5. Positron emission tomography (PET) images from patients with u
FDG). (A) FDG-PET (left column), computed tomography (CT) angio
ymptomatic carotid stenosis (top row) and contralateral asymptomatic car
orresponding to stenotic carotid plaque. (B) A graph showing FDG accumula
DG uptake into symptomatic plaque was significantly higher. Modified, withlaced in contact with the arterial intima could detect high
DG uptake in atherosclerotic segments of the iliac artery.
hese studies coincided with reports that approximately
0% of patients undergoing FDG-PET for cancer were
ound, incidentally, also to have high FDG uptake into large
rteries (36), assumed to be due to atherosclerosis. Com-
ared with those with no vascular uptake, the patients with
igh vascular FDG uptake had more risk factors for
therosclerosis (37). These studies strongly suggested that
therosclerotic plaques could be imaged by FDG-PET.
ndeed, it is now recognized that atherosclerotic FDG
ptake might be misinterpreted as representing the presence
f tumor in oncological scans (38).
The first clinical study of FDG-PET imaging of human
therosclerosis was published recently (39). In this study
udd et al. used autoradiography to demonstrate that when
uman atherosclerotic plaques are incubated ex vivo, triti-
ted deoxyglucose are taken up by plaque macrophages but
ot by surrounding vascular smooth muscle cells or normal
essel. They subsequently undertook FDG-PET scans on
ight patients who had experienced a recent TIA and in
hom there was angiographic evidence of internal carotid
rtery stenosis. The FDG-PET images were co-registered
ith computed tomography (CT) angiograms to ensure that
ny PET “hot spots” coincided with identified stenotic
laques. They demonstrated FDG accumulation into all
ight symptomatic plaques with significantly less FDG
ptake into six contralateral asymptomatic plaques (differ-
le carotid disease after administration of fluorine-18–labeled deoxyglucose
y (middle column), and fused (right column) images from patient with
tenosis (bottom row). The yellow arrows highlight areas of FDG uptakenstab
graph
otid stion rate in symptomatic versus asymptomatic carotid plaques. Note that
permission, from original figure by Rudd et al. (39).
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April 18, 2006:C57–68 Nuclear Imaging of Vulnerable Plaquence in mean FDG uptake rate of 2.1  105 s1, p 
.005) and no discernable uptake into normal arteries (Fig. 5).
These studies provide proof of principal that FDG-PET
an image atherosclerotic plaque inflammation and suggest
hat it can also quantify plaque inflammatory cell activity. If
onfirmed, these observations suggest that FDG-PET
ould be used to identify potentially unstable plaques and to
onitor effects of drug therapy on plaque inflammation.
onfirmation that FDG-PET can quantify plaque macro-
hages has come from a recent study in atherosclerotic
abbits that demonstrated a close correlation between FDG
ptake and plaque macrophage content (r  0.81, p 
.0001) (40). If FDG-PET is able to identify only those
laques that are most actively inflamed, then it follows that
ot all plaques should take up significant amounts of FDG.
t is becoming clear that this is indeed the case. Three
tudies have been published recently in which patients with
uspected cancer were imaged by both CT and FDG-PET
41–43). Computed tomography measures calcium, which
s an almost universal component of atherosclerosis, such
hat the presence or absence of calcium in the vessel wall is
aken to include or exclude the presence of atherosclerosis
44). All studies demonstrated substantial disparity between
T positive and PET positive plaques (Fig. 6); however,
hese findings are not inconsistent with current understand-
ng of plaque cell biology that would predict that calcifica-
ion is a consequence of cell death induced by inflammation.
hus FDG uptake indicates current inflammation and there-
ore potential instability, whereas CT calcification identifies
ast inflammation and, therefore, relative stability (45).
These studies all suggest that FDG-PET might have an
mportant role to play in identifying vulnerable plaques,
lthough this approach has a number of important limita-
igure 6. Images obtained by combined positron emission tomography (P
abeled deoxyglucose (FDG) in patients with aortic atheroma. Top row: c
alcium present in the aortic wall on CT. On the PET and fused images gr
all. Bottom row: transaxial CT (left), FDG-PET (middle), and fused (r
ide of the descending aorta (arrow), which on the FDG-PET and fused im
rade 3 FDG uptake is also seen on the lateral side of descending aorta (ar
on-calcified vessel wall. Modified, with permission, from Tatsumi et al. (42).ions that must be overcome if it is to be of wider clinical
se. Fluorine-18–labeled deoxyglucose PET provides little
r no anatomical resolution and so must be combined and
o-registered with another imaging modality to ensure that
he PET signal arises from an atherosclerotic plaque and not
n adjacent metabolically active structure, such as a lymph
ode. This will no doubt be facilitated by the wider
vailability of combined PET/CT scanners; however, any
o-registered imaging modality that relies on angiographic
rincipals will be no better at identifying non-stenotic
esions than conventional angiography. Co-registration with
igh resolution magnetic resonance imaging (MRI), which
an characterize non-stenotic as well as stenotic lesions,
ffers promise for imaging large arteries, such as the carotid.
t also has the advantage of not adding to radiation
xposure. Our group has recently completed a study in
hich both FDG-PET and MRI were carried out on a
ohort of patients (n  12) with symptomatic carotid
isease, due to undergo carotid endarterectomy (46). Sur-
risingly, we found that 5 of 12 plaques targeted for
ndarterectomy had the same degree of FDG uptake as
ormal vessel wall. In addition, non-stenotic plaques with
igh FDG uptake were identified in three of these five
atients. This study reinforces the advantages of combining
DG-PET with MRI and suggests that this technique
ight provide a method of selecting appropriate lesions for
urgical or percutaneous intervention in patients at risk of
troke. Unfortunately, however, combined MRI/PET scan-
ers are a long way off, and artifacts generated by movement
ake imaging small vessels, such as the coronary artery,
roblematic.
The high background uptake of glucose into the myocar-
ium also poses particular problems for the use of FDG-
omputed tomography (CT) machine after administration of fluorine-18–
l CT (left), FDG-PET (middle), and fused (right) images. There is no
(arrows) and grade 3 (arrowheads), FDG uptake can be seen in the aortic
images. The CT image shows marked calcification present on the medial
demonstrates grade 1 FDG uptake (arrows) indicating mild inflammation.ET)/c
orona
ade 1
ight)
agesrowheads) indicating a higher level of inflammation in this segment of
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l. (43) have been able to identify FDG uptake in coronary
rteries of oncological patients from images obtained from a
ombined PET/CT scanner (Fig. 7). Coronary FDG up-
ake was found to be most often proximal and multifocal,
hich agrees with autopsy studies that coronary inflamma-
ion occurs at multiple sites simultaneously (47). Myocardial
nd hepatic FDG uptake, however, did prevent evaluation
f coronary arteries in approximately one-half of the pa-
ients studied, and therefore in the future the use of
re-imaging beta-blockade might be necessary to suppress
yocardial uptake (48). Despite these results, coronary
theroma imaging will probably be better achieved either
ith a more macrophage-specific ligand than FDG or by
abeling other plaque-specific ligands with positron emit-
ers. Finally, if PET is to be used to monitor changes in
laque composition over time, then the technique will have
igure 7. Images from combined positron emission tomography (PET)
eoxyglucose (FDG) uptake. Fused PET/CT images show contiguous tran
istal to the calcified left anterior descending artery (arrow). A tumor sitso be refined to limit radiation exposure. oONCLUSIONS
ntil recently, imaging technology for atherosclerosis has
ocused almost entirely on defining anatomic obstructions to
ow; however, advances in our understanding of the cell
iology that leads to clinical events in atherosclerosis have
ighlighted a clear need for imaging techniques that can
rovide information about plaque composition. Imaging
nd quantification of inflammation within atherosclerotic
laques remain important goals with respect to identifica-
ion and treatment of vulnerable plaques both in the
arotid circulation where there is a correlation with stroke
isk and in the coronary vasculature where plaque rupture
ften leads to myocardial infarction and/or death. Although
he different approaches described previously do hold prom-
se, no large in vivo prospective trials have been carried out,
nd unless time, effort, and finance is aimed in the direction
puted tomography (CT) scanner showing coronary fluorine-18–labeled
l slices through heart. Inflammation (arrowheads) is present proximal and
ent to esophagus. Reprinted, with permission, from Dunphy et al. (43)./com
saxia
adjacf nuclear imaging, we are unlikely to find a suitable
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April 18, 2006:C57–68 Nuclear Imaging of Vulnerable Plaqueon-invasive method for coronary imaging in the near
uture. At the present time FDG-PET seems to be the
ost promising technique for identifying inflamed le-
ions in the peripheral and carotid circulation. The supe-
ior spatial resolution of PET, along with the anatomical
o-registration demonstrated by Rudd et al. (39) and Ben
aim et al. (41), increases the potential for imaging plaque
nflammation and allows for more sophisticated levels of
uantification, such as calculation of plaque glucose meta-
olic rate; however, FDG-PET is unlikely to provide the
nswer for non-invasive coronary plaque imaging unless
DG uptake in the adjacent myocardium can be adequately
uppressed. Annexin-A5 and MMP tracers are not taken up
y the healthy myocardium and therefore could be used for
oronary imaging, although they will need to be labeled
ith positron emitting radionuclides in order to use the
uperior imaging and quantification capabilities of PET,
nd anatomical co-registration—for example with multislice
T images—would be necessary to localize tracer uptake to
articular coronary segments. The problem of cardiac and
espiratory motion will also need to be addressed, and this is
ikely to be done by using a combination of respiratory and
lectrocardiographic gating. Hopefully the future will bring
urther advances in both tracer and detector technologies
hat will make non-invasive coronary plaque imaging a
eality. For now, nuclear imaging of inflammation within
therosclerotic plaques remains in the research domain.
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